United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

medac uk - pamidronate disodium - solution for infusion - 3mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

medac uk - pamidronate disodium - solution for infusion - 3mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

medac uk - pamidronate disodium - solution for infusion - 3mg/1ml

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - pamidronate disodium, quantity: 9 mg - injection, concentrated - excipient ingredients: sodium hydroxide; water for injections; phosphoric acid; mannitol - treatment of conditions associated with increased osteoclast activity predominantly lytic bone metastases from breast cancer and advanced multiple myeloma. acute management of tumour-induced hypercalcaemia (hypercalcaemia of malignancy). treatment of symptomatic paget's disease of bone.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - pamidronate disodium, quantity: 6 mg - injection, concentrated - excipient ingredients: mannitol; water for injections; sodium hydroxide; phosphoric acid - treatment of conditions associated with increased osteoclast activity predominantly lytic bone metastases from breast cancer and advanced multiple myeloma. acute management of tumour-induced hypercalcaemia (hypercalcaemia of malignancy). treatment of symptomatic paget's disease of bone.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - pamidronate disodium, quantity: 3 mg - injection, concentrated - excipient ingredients: mannitol; phosphoric acid; water for injections; sodium hydroxide - treatment of conditions associated with increased osteoclast activity predominantly lytic bone metastases from breast cancer and advanced multiple myeloma. acute management of tumour-induced hypercalcaemia (hypercalcaemia of malignancy). treatment of symptomatic paget's disease of bone.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - pamidronate disodium, quantity: 3 mg - injection, concentrated - excipient ingredients: phosphoric acid; mannitol; sodium hydroxide; water for injections - treatment of conditions associated with increased osteoclast activity: predominantly lytic bone metastases from breast cancer and advanced multiple myeloma. acute management of tumour-induced hypercalcaemia (hypercalcaemia of malignancy). treatment of symptomatic paget's disease of bone.

Malta - English - Medicines Authority

wockhardt uk limited - pamidronate disodium - concentrate for solution for infusion - pamidronate disodium 15 mg/ml - drugs for treatment of bone diseases

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - pamidronic acid 12.63mg equivalent to 15 mg disodium pamidronate - solution for infusion - 15 mg/5ml - active: pamidronic acid 12.63mg equivalent to 15 mg disodium pamidronate excipient: mannitol phosphoric acid sodium hydroxide water for injection - treatment of conditions associated with increased osteoclast activity: · predominantly lytic bone metastases from breast cancer and advanced multiple myeloma

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - pamidronic acid 25.27mg equivalent to 30 mg disodium pamidronate - solution for infusion - 30 mg/10ml - active: pamidronic acid 25.27mg equivalent to 30 mg disodium pamidronate excipient: mannitol phosphoric acid sodium hydroxide water for injection - treatment of conditions associated with increased osteoclast activity: · predominantly lytic bone metastases from breast cancer and advanced multiple myeloma